Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.

Immunology - 1 Nov 2017

Lynch Adam, Hawk William, Nylen Emily, Ober Sean, Autin Pierre, Barber Amorette

Abstract excerpt

Adoptive transfer of T cells is a promising cancer therapy and expression of chimeric antigen receptors can enhance tumour recognition and T-cell effector functions. The programmed death protein 1 (PD1) receptor is a prospective target for a chimeric antigen receptor because PD1 ligands are expressed on many cancer types, including lymphoma. Therefore, we developed a murine chimeric PD1 receptor (chPD1)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adoptive Transfer
Share to CD28 Antigens
Share to CD3 Complex

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukocyte Common Antigens

Share to Lymphoma, T-Cell

Share to Mice, Congenic

Share to Neoplasms, Experimental

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 28670716
DOI: 10.1111/imm.12784
PMCID: PMC5629437

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.PMID 28670716Read ↗

Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptorSemantic proximity Read ↗

A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasisSemantic proximity Read ↗

A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.Semantic proximity Read ↗

PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivoSemantic proximity Read ↗

An immune-stimulating antibody conjugate spatiotemporally targeting CD47 and TLR9 elicits macrophage-dependent tumor clearance and durable anti-cancer adaptive immunitySemantic proximity Read ↗

A novel single TCR gamma chain fused with antibody-based binding domain facilitates T cell cytotoxicity for potent anti-tumor response without forming TCR-CD3 complexSemantic proximity Read ↗

Adoptive Cell Therapy—Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen ReceptorsSemantic proximity Read ↗

Targeting CAR to the Peptide-MHC Complex Reveals Distinct Signaling Compared to That of TCR in a Jurkat T Cell ModelSemantic proximity Read ↗

MR1-restricted T cells: the new dawn of cancer immunotherapy.Semantic proximity Read ↗

PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.Semantic proximity Read ↗

Solid tumor immunotherapy using NKG2D-based adaptor CAR T cellsSemantic proximity Read ↗

Coexpression of c-Jun in multiple-chain DAP-CAR-engineered T-cells for solid tumor therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.